Simulations Plus(US:SLP) Seeking Alpha·2025-09-11 16:15Core Insights - Simulations Plus is celebrating its 30th anniversary, indicating its established presence in the biosimulation market [2] - The company utilizes a combination of technology, science, mathematics, and various disciplines to develop in silico models that enhance drug development efficiency [3] Company Overview - Simulations Plus offers a comprehensive platform that supports various stages of drug development, from early discovery to clinical studies and post-approval applications [4] - The platform includes applications for lead optimization, preclinical translational impact, and modeling that supports bioequivalence waivers [4] Industry Context - Biosimulation has gained acceptance over the years from scientific and drug sponsor perspectives, highlighting its importance in the drug development process [5]